Collateral for a security interest recorded Oct 24, 2024 (Ascent Partners Fund LLC).
Term ends Apr 17, 2029 · High confidence
20-year base term ends Apr 17, 2029
Held by Reshape Lifesciences Inc.
Filed Jul 11, 2012 as application 13/546,204 · Granted Apr 2, 2013
Base term, 20 years from filing
Today
2009
2029
Clock starts
Apr 17, 2009
Apr 17, 2009
Term ends
Apr 17, 2029
Apr 17, 2029
Granted
Apr 2, 2013
Apr 2, 2013
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 17, 2009, when application 12/426,057, the earliest non-provisional in its chain, was filed (this one was filed Jul 11, 2012) | Apr 17, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 17, 2029 | High confidence |
This family
| US 9,023,062 | In force Jul 2031 | Jul 2031 |
| US 9,023,063 | In force Jul 2030 | Jul 2030 |
| US 8,398,654 | Lapsed on the fee record Mar 2021 | Mar 2021 |
| US 8,409,221 | this patent Apr 2029 | Apr 2029 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 22, 2013 Reel 31451, frame 488 | Franklin, Ethan; Olroyd, Craig; Mudd, Christopher S. | Allergan, Inc. | Assignment of Assignor's Interest |
| Dec 2, 2013 Reel 31747, frame 761 | Allergan, Inc. | Apollo Endosurgery, Inc. | Assignment of Assignor's Interest |
| Dec 3, 2013 Reel 31756, frame 729 | Apollo Endosurgery, Inc. | Oxford Finance LLC, as Agent | Security Agreement |
| Mar 2, 2015 Reel 35120, frame 740 | Oxford Finance LLC, as Agent | Apollo Endosurgery, Inc. | Termination of Patent Security Interest (Recorded on 12/3/13 at Reel/Frame 031756/0729 and on 1/2/14 at Reel/Frame 031910/0460) |
| Mar 2, 2015 Reel 35120, frame 843 | Apollo Endosurgery, Inc. | Athyrium Opportunities II Acquisition LP, as Administrative Agent | Notice of Grant of Security Interest in Patents |
| Dec 30, 2016 Reel 41224, frame 821 | Apollo Endosurgery US, Inc. | Athyrium Opportunities II Acquisition LP, as Administrative Agent | Notice of Grant of Security Interest in Patents |
| Mar 27, 2017 Reel 42106, frame 912 | Apollo Endosurgery, Inc. | Apollo Endosurgery US, Inc. | Change of Name |
| Jan 4, 2019 Reel 48012, frame 902 | Athyrium Opportunities II Acquisition LP, as Administrative Agent | Apollo Endosurgery US, Inc. | Termination and Release of Security Interest in Patents |
| Apr 15, 2019 Reel 48885, frame 687 | Apollo Endosurgery US, Inc. | Solar Capital Ltd., as Collateral Agent | Intellectual Property Security Agreement |
| Sep 22, 2020 Reel 53846, frame 556 | Apollo Endosurgery US, Inc. | Reshape Lifesciences Inc. | Assignment of Assignor's Interest |
| Dec 30, 2021 Reel 58599, frame 297 | SLR Investment Corp. (F/K/A Solar Capital Ltd.) | Apollo Endosurgery US, Inc.; Apollo Endosurgery International, LLC; Apollo Endosurgery, Inc.; Lpath Therapeutics Inc. | Release of Security Interest |
| Dec 30, 2021 reel/frame not recorded | SLR Investment Corp. (F/K/A Solar Capital Ltd.) | Apollo Endosurgery US, Inc. | Release of Security Interest |
| Dec 30, 2021 reel/frame not recorded | SLR Investment Corp. (F/K/A Solar Capital Ltd.) | Apollo Endosurgery International, LLC | Release of Security Interest |
| Dec 30, 2021 reel/frame not recorded | SLR Investment Corp. (F/K/A Solar Capital Ltd.) | Apollo Endosurgery, Inc. | Release of Security Interest |
| Dec 30, 2021 reel/frame not recorded | SLR Investment Corp. (F/K/A Solar Capital Ltd.) | Lpath Therapeutics Inc. | Release of Security Interest |
| Oct 24, 2024 Reel 70166, frame 882 | Reshape Lifesciences Inc. | Ascent Partners Fund LLC | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2029
Term ends Apr 17, 2029. No further fees fall due before then
Citations
18
later US patents cite this one
That is above the median of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.